Walgreens Teams Up with Boehringer Ingelheim for Obesity Treatment Clinical Trials

Walgreens Boots Alliance has partnered with Boehringer Ingelheim to advance clinical trials aimed at treating obesity and type 2 diabetes. As part of the collaboration, Walgreens will utilize select community pharmacies as clinical trial sites to recruit participants, particularly targeting overweight individuals, those living with obesity, and patients with type 2 diabetes.

The partnership is designed to improve accessibility and enhance equitable health representation in clinical trials, with a specific focus on Black and Hispanic adults, according to both companies. In addition, Boehringer Ingelheim has teamed up with EmVenio Research to introduce mobile research units, expanding the initiative’s reach and offering more options for participation.

Walgreens first entered the clinical trial sector in June 2022, marking a significant expansion of its healthcare services. Since then, the company has secured over 35 clinical trial contracts with various pharmaceutical companies, continuing to grow its presence in the healthcare field.